1
|
Foltynie T, Bruno V, Fox S, Kühn AA, Lindop F, Lees AJ. Medical, surgical, and physical treatments for Parkinson's disease. Lancet 2024; 403:305-324. [PMID: 38245250 DOI: 10.1016/s0140-6736(23)01429-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Revised: 05/09/2023] [Accepted: 07/06/2023] [Indexed: 01/22/2024]
Abstract
Although dopamine replacement therapy remains a core component of Parkinson's disease treatment, the onset of motor fluctuations and dyskinetic movements might require a range of medical and surgical approaches from a multidisciplinary team, and important new approaches in the delivery of dopamine replacement are becoming available. The more challenging, wide range of non-motor symptoms can also have a major impact on the quality of life of a patient with Parkinson's disease, and requires careful multidisciplinary management using evidence-based knowledge, as well as appropriately tailored strategies according to the individual patient's needs. Disease-modifying therapies are urgently needed to prevent the development of the most disabling refractory symptoms, including gait and balance difficulties, cognitive impairment and dementia, and speech and swallowing impairments. In the third paper in this Series, we present the latest evidence supporting the optimal treatment of Parkinson's disease, and describe an expert approach to many aspects of treatment choice where an evidence base is insufficient.
Collapse
Affiliation(s)
- Tom Foltynie
- Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
| | - Veronica Bruno
- Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
| | - Susan Fox
- Edmond J Safra Program in Parkinson Disease, Krembil Brain Institute, Toronto Western Hospital, Toronto, ON, Canada; Division of Neurology, University of Toronto, Toronto, ON, Canada
| | - Andrea A Kühn
- Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Berlin, Germany; NeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, Berlin, Germany; Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Fiona Lindop
- University Hospitals of Derby and Burton NHS Foundation Trust, Specialist Rehabilitation, Florence Nightingale Community Hospital, Derby, UK
| | - Andrew J Lees
- Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK; Reta Lila Weston Institute of Neurological Studies, University College London, London, UK
| |
Collapse
|
2
|
Bai Y, Yin Z, Diao Y, Hu T, Yang A, Meng F, Zhang J. Loss of long-term benefit from VIM-DBS in essential tremor: A secondary analysis of repeated measurements. CNS Neurosci Ther 2021; 28:279-288. [PMID: 34866345 PMCID: PMC8739044 DOI: 10.1111/cns.13770] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Revised: 10/18/2021] [Accepted: 11/16/2021] [Indexed: 11/26/2022] Open
Abstract
AIMS Deep brain stimulation (DBS) in the ventral intermediate nucleus (Vim-DBS) is the preferred surgical therapy for essential tremor (ET). Tolerance and disease progression are considered to be the two main reasons underlying the loss of long-term efficacy of Vim-DBS. This study aimed to explore whether Vim-DBS shows long-term loss of efficacy and to evaluate the reasons for this diminished efficacy from different aspects. METHODS In a repeated-measures meta-analysis of 533 patients from 18 studies, Vim-DBS efficacy was evaluated at ≤6 months, 7-12 months, 1-3 years, and ≥4 years. The primary outcomes were the score changes in different components of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS; total score, motor score, hand-function score, and activities of daily living [ADL] score). Secondary outcomes were the long-term predictive factors. RESULTS The TRS total, motor, and ADL scores showed significant deterioration with disease progression (p = 0.002, p = 0.047, and p < 0.001, respectively), while the TRS total (p < 0.001), hand-function (p = 0.036), and ADL (p = 0.004) scores indicated a significant long-term reduction in DBS efficacy, although the motor subscore indicated no loss of efficacy. Hand-function (p < 0.001) and ADL (p = 0.028) scores indicated DBS tolerance, while the TRS total and motor scores did not. Stimulation frequency and preoperative score were predictive factors for long-term results. CONCLUSION This study provides level 3a evidence that long-term Vim-DBS is effective in controlling motor symptoms without waning benefits. The efficacy reduction for hand function was caused by DBS tolerance, while that for ADL was caused by DBS tolerance and disease progression. More attention should be given to actual functional recovery rather than changes in motor scores in patients with ET.
Collapse
Affiliation(s)
- Yutong Bai
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Neurostimulation, Beijing, China
| | - Zixiao Yin
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Neurostimulation, Beijing, China
| | - Yu Diao
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Neurostimulation, Beijing, China
| | - Tianqi Hu
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Neurostimulation, Beijing, China
| | - Anchao Yang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Neurostimulation, Beijing, China
| | - Fangang Meng
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Neurostimulation, Beijing, China
| | - Jianguo Zhang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Neurostimulation, Beijing, China
| |
Collapse
|
3
|
Chen T, Lin F, Cai G. Comparison of the Efficacy of Deep Brain Stimulation in Different Targets in Improving Gait in Parkinson's Disease: A Systematic Review and Bayesian Network Meta-Analysis. Front Hum Neurosci 2021; 15:749722. [PMID: 34744665 PMCID: PMC8568957 DOI: 10.3389/fnhum.2021.749722] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Accepted: 09/02/2021] [Indexed: 12/01/2022] Open
Abstract
Background: Although a variety of targets for deep brain stimulation (DBS) have been found to be effective in Parkinson's disease (PD), it remains unclear which target for DBS leads to the best improvement in gait disorders in patients with PD. The purpose of this network meta-analysis (NMA) is to compare the efficacy of subthalamic nucleus (STN)-DBS, internal globus pallidus (GPi)-DBS, and pedunculopontine nucleus (PPN)-DBS, in improving gait disorders in patients with PD. Methods: We searched the PubMed database for articles published from January 1990 to December 2020. We used various languages to search for relevant documents to reduce language bias. A Bayesian NMA and systematic review of randomized and non-randomized controlled trials were conducted to explore the effects of different targets for DBS on gait damage. Result: In the 34 included studies, 538 patients with PD met the inclusion criteria. The NMA results of the effect of the DBS “on and off” on the mean change of the gait of the patients in medication-off show that GPi-DBS, STN-DBS, and PPN-DBS are significantly better than the baseline [GPi-DBS: –0.79(–1.2, –0.41), STN-DBS: –0.97(–1.1, –0.81), and PPN-DBS: –0.56(–1.1, –0.021)]. According to the surface under the cumulative ranking (SUCRA) score, the STN-DBS (SUCRA = 74.15%) ranked first, followed by the GPi-DBS (SUCRA = 48.30%), and the PPN-DBS (SUCRA = 27.20%) ranked last. The NMA results of the effect of the DBS “on and off” on the mean change of the gait of the patients in medication-on show that, compared with baseline, GPi-DBS and STN-DBS proved to be significantly effective [GPi-DBS: –0.53 (–1.0, –0.088) and STN-DBS: –0.47(–0.66, –0.29)]. The GPi-DBS ranked first (SUCRA = 59.00%), followed by STN-DBS(SUCRA = 51.70%), and PPN-DBS(SUCRA = 35.93%) ranked last. Conclusion: The meta-analysis results show that both the STN-DBS and GPi-DBS can affect certain aspects of PD gait disorder.
Collapse
Affiliation(s)
- Tianyi Chen
- School of Mathematics, Shandong University, Jinan, China
| | - Fabin Lin
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.,Fujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, China
| | - Guoen Cai
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.,Fujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, China
| |
Collapse
|
4
|
Lin F, Wu D, Yu J, Weng H, Chen L, Meng F, Chen Y, Ye Q, Cai G. Comparison of efficacy of deep brain stimulation and focused ultrasound in parkinsonian tremor: a systematic review and network meta-analysis. J Neurol Neurosurg Psychiatry 2021; 92:jnnp-2020-323656. [PMID: 33461975 DOI: 10.1136/jnnp-2020-323656] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 10/25/2020] [Accepted: 12/22/2020] [Indexed: 02/07/2023]
Abstract
To compare the efficacy of deep brain stimulation (DBS) and MRI-guided focused ultrasound (MRIgFUS) in parkinsonian tremor. We performed a network meta-analysis based on a Bayesian framework. We searched the literature for articles published between January 1990 and October 2020 using three databases: PubMed, Embase and Cochrane Library (The Cochrane Database of Systematic Reviews). A total of 24 studies were included in our analysis, comprising data from 784 participants. Our findings revealed similar efficacy of DBS and MRIgFUS in parkinsonian tremor suppression. Compared with internal globus pallidus (GPi)-MRIgFUS, GPi-DBS -1.84 (-6.44, 2.86), pedunculopontine nucleus (PPN)_DBS -3.28 (-9.28, 2.78), PPN and caudal zona incerta (cZI)-DBS 0.40 (-6.16, 6.87), subthalamic nucleus (STN)_DBS 0.89 (-3.48, 5.30), STN and cZI-DBS 1.99 (-4.74, 8.65), ventral intermediate nucleus(VIM)_DBS 1.75 (-2.87, 6.48), VIM_FUS 0.72 (-5.27, 6.43), cZI-DBS 0.27 (-4.75, 5.36) were no significantly difference. Compared with VIM-MRIgFUS, GPi-DBS -2.55(-6.94, 2.21), GPi-FUS -0.72 (-6.43, 5.27), PPN_DBS -4.01(-9.97, 2.11), PPN and cZI-DBS -0.32 (-6.73, 6.36), STN_DBS 0.16 (-3.98, 4.6), STN and cZI-DBS 1.31(-5.18,7.87), VIM-DBS 1.00(-3.41, 5.84)and cZI-DBS -0.43 (-5.07, 4.68) were no significantly difference. With respect to the results for the treatment of motor symptoms, GPi-DBS, GPi-MRIgFUS, STN-DBS and cZI-DBS were significantly more efficacious than baseline (GPi-DBS 15.24 (5.79, 24.82), GPi-MRIgFUS 13.46 (2.46, 25.10), STN-DBS 19.62 (12.19, 27.16), cZI-DBS 14.18 (1.73, 26.89). The results from the surface under the cumulative ranking results showed that STN-DBS ranked first, followed by combined PPN and cZI-DBS, and PPN-DBS ranked last. MRIgFUS, an efficacious intervention for improving parkinsonian tremor, has not demonstrated to be inferior to DBS in parkinsonian tremor suppression. Hence, clinicians should distinguish individual patients' symptoms to ensure that the appropriate intervention and therapeutic approach are applied.
Collapse
Affiliation(s)
- Fabin Lin
- Department of Neurology, Union Hospital, Fujian Medical University, Fuzhou, China
- Institute or Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China
- Department of Clinical Medicine, Fujian Medical University, Fuzhou, China
| | - Dihang Wu
- Department of Neurology, Union Hospital, Fujian Medical University, Fuzhou, China
- Institute or Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China
- Department of Clinical Medicine, Fujian Medical University, Fuzhou, China
| | - Jiao Yu
- Department of Neurology, Union Hospital, Fujian Medical University, Fuzhou, China
- Institute or Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China
- Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China
| | - Huidan Weng
- Department of Neurology, Union Hospital, Fujian Medical University, Fuzhou, China
- Institute or Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China
- Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China
| | - Lina Chen
- Department of Neurology, Union Hospital, Fujian Medical University, Fuzhou, China
- Institute or Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China
- Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China
| | - Fangang Meng
- Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
| | - Ying Chen
- Department of Neurology, Union Hospital, Fujian Medical University, Fuzhou, China
- Institute or Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China
- Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China
| | - Qinyong Ye
- Department of Neurology, Union Hospital, Fujian Medical University, Fuzhou, China
- Institute or Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China
- Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China
| | - Guoen Cai
- Department of Neurology, Union Hospital, Fujian Medical University, Fuzhou, China
- Institute or Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China
- Department of Clinical Medicine, Fujian Medical University, Fuzhou, China
- Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China
| |
Collapse
|
5
|
Giordano M, Caccavella VM, Zaed I, Foglia Manzillo L, Montano N, Olivi A, Polli FM. Comparison between deep brain stimulation and magnetic resonance-guided focused ultrasound in the treatment of essential tremor: a systematic review and pooled analysis of functional outcomes. J Neurol Neurosurg Psychiatry 2020; 91:1270-1278. [PMID: 33055140 DOI: 10.1136/jnnp-2020-323216] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Revised: 08/22/2020] [Accepted: 09/09/2020] [Indexed: 01/01/2023]
Abstract
The current gold standard surgical treatment for medication-resistant essential tremor (ET) is deep brain stimulation (DBS). However, recent advances in technologies have led to the development of incisionless techniques, such as magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy. The authors perform a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement to compare unilateral MRgFUS thalamotomy to unilateral and bilateral DBS in the treatment of ET in terms of tremor severity and quality of life improvement. PubMed, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials and SCOPUS databases were searched. 45 eligible articles, published between 1990 and 2019, were retrieved. 1202 patients were treated with DBS and 477 were treated with MRgFUS thalamotomy. Postoperative tremor improvement was greater following DBS than MRgFUS thalamotomy (p<0.001). A subgroup analysis was carried out stratifying by treatment laterality: bilateral DBS was significantly superior to both MRgFUS and unilateral DBS (p<0.001), but no significant difference was recorded between MRgFUS and unilateral DBS (p<0.198). Postoperative quality of life improvement was significantly greater following MRgFUS thalamotomy than DBS (p<0.001). Complications were differently distributed among the two groups (p<0.001). Persistent complications were significantly more common in the MRgFUS group (p=0.042). While bilateral DBS proves superior to unilateral MRgFUS thalamotomy in the treatment of ET, a subgroup analysis suggests that treatment laterality is the most significant determinant of tremor improvement, thus highlighting the importance of future investigations on bilateral staged MRgFUS thalamotomy.
Collapse
Affiliation(s)
- Martina Giordano
- Department of Neurosurgery, University Hospital Agostino Gemelli, Roma, Italy
| | | | - Ismail Zaed
- Department of Neurosurgery, Humanitas Clinical and Research Center, Rozzano, Italy
| | | | - Nicola Montano
- Department of Neurosurgery, University Hospital Agostino Gemelli, Roma, Italy
| | - Alessandro Olivi
- Department of Neurosurgery, University Hospital Agostino Gemelli, Roma, Italy
| | - Filippo Maria Polli
- Department of Neurosurgery, University Hospital Agostino Gemelli, Roma, Italy
| |
Collapse
|
6
|
Wang KL, Ren Q, Chiu S, Patel B, Meng FG, Hu W, Shukla AW. Deep brain stimulation and other surgical modalities for the management of essential tremor. Expert Rev Med Devices 2020; 17:817-833. [PMID: 33081571 DOI: 10.1080/17434440.2020.1806709] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
INTRODUCTION Surgical treatments are considered for essential tremor (ET) when patients do not respond to oral pharmacological therapies. These treatments mainly comprise radiofrequency (RF) thalamotomy, gamma knife radiosurgery (GKRS), deep brain stimulation (DBS), and focused ultrasound (FUS) procedures. AREAS COVERED We reviewed the strengths and weaknesses of each procedure and clinical outcomes for 7 RF studies (n = 85), 11 GKRS (n = 477), 33 DBS (n = 1061), and 13 FUS studies (n = 368). A formal comparison was not possible given the heterogeneity in studies. Improvements were about 42%-90% RF, 10%-79% GKRS, 45%-83% DBS, 42%-83% FUS at short-term follow-up (<12 months) and were about 54%-82% RF, 11%-84% GKRS, 18%-92% DBS, and 42%-80% FUS at long-term follow-up (>12 months). EXPERT OPINION We found DBS with inherent advantages of being an adjustable and reversible procedure as the most frequently employed surgical procedure for control of ET symptoms. FUS is a promising procedure but has limited applicability for unilateral control of symptoms. RF is invasive, and GKRS has unpredictable delayed effects. Each of these surgical modalities has advantages and limitations that need consideration when selecting a treatment for the ET patients.
Collapse
Affiliation(s)
- Kai-Liang Wang
- Department of Neurosurgery, Xuanwu Hospital, Capital Medical University , Beijing, China.,Department of Functional Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University , Beijing, China
| | - Qianwei Ren
- Department of Functional Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University , Beijing, China
| | - Shannon Chiu
- Department of Neurology, University of Florida College of Medicine , Gainesville, FL, USA
| | - Bhavana Patel
- Department of Neurology, University of Florida College of Medicine , Gainesville, FL, USA
| | - Fan-Gang Meng
- Department of Functional Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University , Beijing, China
| | - Wei Hu
- Department of Neurology, University of Florida College of Medicine , Gainesville, FL, USA
| | - Aparna Wagle Shukla
- Department of Neurology, University of Florida College of Medicine , Gainesville, FL, USA
| |
Collapse
|
7
|
Jung NY, Park CK, Chang WS, Jung HH, Chang JW. Effects on cognition and quality of life with unilateral magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. Neurosurg Focus 2019; 44:E8. [PMID: 29385928 DOI: 10.3171/2017.11.focus17625] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Although neurosurgical procedures are effective treatments for controlling involuntary tremor in patients with essential tremor (ET), they can cause cognitive decline, which can affect quality of life (QOL). The purpose of this study is to assess the changes in the neuropsychological profile and QOL of patients following MR-guided focused ultrasound (MRgFUS) thalamotomy for ET. METHODS The authors prospectively analyzed 20 patients with ET who underwent unilateral MRgFUS thalamotomy at their institute in the period from March 2012 to September 2014. Patients were regularly evaluated with the Clinical Rating Scale for Tremor (CRST), neuroimaging, and cognition and QOL measures. The Seoul Neuropsychological Screening Battery was used to assess cognitive function, and the Quality of Life in Essential Tremor Questionnaire (QUEST) was used to evaluate the postoperative change in QOL. RESULTS The total CRST score improved by 67.3% (from 44.75 ± 9.57 to 14.65 ± 9.19, p < 0.001) at 1 year following MRgFUS thalamotomy. Mean tremor scores improved by 68% in the hand contralateral to the thalamotomy, but there was no significant improvement in the ipsilateral hand. Although minimal cognitive decline was observed without statistical significance, memory function was much improved (p = 0.031). The total QUEST score also showed the same trend of improving (64.16 ± 17.75 vs 27.38 ± 13.96, p < 0.001). CONCLUSIONS The authors report that MRgFUS thalamotomy had beneficial effects in terms of not only tremor control but also safety for cognitive function and QOL. Acceptable postoperative changes in cognition and much-improved QOL positively support the clinical significance of MRgFUS thalamotomy as a new, favorable surgical treatment in patients with ET.
Collapse
Affiliation(s)
- Na Young Jung
- Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Chang Kyu Park
- Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Won Seok Chang
- Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Hyun Ho Jung
- Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Jin Woo Chang
- Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
8
|
Paschen S, Forstenpointner J, Becktepe J, Heinzel S, Hellriegel H, Witt K, Helmers AK, Deuschl G. Long-term efficacy of deep brain stimulation for essential tremor: An observer-blinded study. Neurology 2019; 92:e1378-e1386. [PMID: 30787161 DOI: 10.1212/wnl.0000000000007134] [Citation(s) in RCA: 65] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Accepted: 11/13/2018] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE Deep brain stimulation (DBS) of the ventral intermediate thalamic nucleus (Vim) is established for medically refractory severe essential tremor (ET), but long-term efficacy is controversial. METHODS Twenty patients with ET with DBS had standardized video-documented examinations at baseline, in the stimulation-on condition at short term (13.1 ± 1.9 months since surgery, mean ± SEM), and in the stimulator switched on and off (stim-ON/OFF) at long term; all assessments were done between 32 and 120 months (71.9 ± 6.9 months) after implantation. The primary outcome was the Tremor Rating Scale (TRS) blindly assessed by 2 trained movement disorder neurologists. Secondary outcomes were TRS subscores A, B, and C; Archimedes spiral score; and activities of daily living score. At long-term follow-up, tremor was additionally recorded with accelerometry. The rebound effect after switching the stimulator off was assessed for 1 hour in a subgroup. RESULTS Tremor severity worsened considerably over time in both in the nonstimulated and stimulated conditions. Vim-DBS improved the TRS in the short term and long term significantly. The spiral score and functional measures showed similar improvements. All changes were highly significant. However, the stimulation effect was negatively correlated with time since surgery (ρ = -0.78, p < 0.001). This was also true for the secondary outcomes. Only one-third of the patients had a rebound effect terminated 60 minutes after the stimulator was switched off. Long-term worsening of the TRS was more profound during stim-ON than in the stim-OFF condition, indicating habituation to stimulation. CONCLUSION Vim-DBS loses efficacy over the long term. Efforts are needed to improve the long-term efficacy of Vim-DBS. CLASSIFICATION OF EVIDENCE This study provides Class IV evidence that for patients with medically refractory severe ET, the efficacy of Vim-DBS severely decreases over 10 years.
Collapse
Affiliation(s)
- Steffen Paschen
- From the Departments of Neurology (S.P., J.F., J.B., S.H., H.H., K.W., G.D.) and Neurosurgery (A.-K.H.), Christian-Albrechts-University; Division of Neurological Pain Research and Therapy (J.F.), Department of Neurology, University Hospital Schleswig-Holstein, Kiel; and Department of Neurology (K.W.), School of Medicine and Health Sciences-European Medical School, University Oldenburg and Research Center Neurosensory Science, Carl von Ossietzky University, Oldenburg, Germany
| | - Julia Forstenpointner
- From the Departments of Neurology (S.P., J.F., J.B., S.H., H.H., K.W., G.D.) and Neurosurgery (A.-K.H.), Christian-Albrechts-University; Division of Neurological Pain Research and Therapy (J.F.), Department of Neurology, University Hospital Schleswig-Holstein, Kiel; and Department of Neurology (K.W.), School of Medicine and Health Sciences-European Medical School, University Oldenburg and Research Center Neurosensory Science, Carl von Ossietzky University, Oldenburg, Germany
| | - Jos Becktepe
- From the Departments of Neurology (S.P., J.F., J.B., S.H., H.H., K.W., G.D.) and Neurosurgery (A.-K.H.), Christian-Albrechts-University; Division of Neurological Pain Research and Therapy (J.F.), Department of Neurology, University Hospital Schleswig-Holstein, Kiel; and Department of Neurology (K.W.), School of Medicine and Health Sciences-European Medical School, University Oldenburg and Research Center Neurosensory Science, Carl von Ossietzky University, Oldenburg, Germany
| | - Sebastian Heinzel
- From the Departments of Neurology (S.P., J.F., J.B., S.H., H.H., K.W., G.D.) and Neurosurgery (A.-K.H.), Christian-Albrechts-University; Division of Neurological Pain Research and Therapy (J.F.), Department of Neurology, University Hospital Schleswig-Holstein, Kiel; and Department of Neurology (K.W.), School of Medicine and Health Sciences-European Medical School, University Oldenburg and Research Center Neurosensory Science, Carl von Ossietzky University, Oldenburg, Germany
| | - Helge Hellriegel
- From the Departments of Neurology (S.P., J.F., J.B., S.H., H.H., K.W., G.D.) and Neurosurgery (A.-K.H.), Christian-Albrechts-University; Division of Neurological Pain Research and Therapy (J.F.), Department of Neurology, University Hospital Schleswig-Holstein, Kiel; and Department of Neurology (K.W.), School of Medicine and Health Sciences-European Medical School, University Oldenburg and Research Center Neurosensory Science, Carl von Ossietzky University, Oldenburg, Germany
| | - Karsten Witt
- From the Departments of Neurology (S.P., J.F., J.B., S.H., H.H., K.W., G.D.) and Neurosurgery (A.-K.H.), Christian-Albrechts-University; Division of Neurological Pain Research and Therapy (J.F.), Department of Neurology, University Hospital Schleswig-Holstein, Kiel; and Department of Neurology (K.W.), School of Medicine and Health Sciences-European Medical School, University Oldenburg and Research Center Neurosensory Science, Carl von Ossietzky University, Oldenburg, Germany
| | - Ann-Kristin Helmers
- From the Departments of Neurology (S.P., J.F., J.B., S.H., H.H., K.W., G.D.) and Neurosurgery (A.-K.H.), Christian-Albrechts-University; Division of Neurological Pain Research and Therapy (J.F.), Department of Neurology, University Hospital Schleswig-Holstein, Kiel; and Department of Neurology (K.W.), School of Medicine and Health Sciences-European Medical School, University Oldenburg and Research Center Neurosensory Science, Carl von Ossietzky University, Oldenburg, Germany
| | - Günther Deuschl
- From the Departments of Neurology (S.P., J.F., J.B., S.H., H.H., K.W., G.D.) and Neurosurgery (A.-K.H.), Christian-Albrechts-University; Division of Neurological Pain Research and Therapy (J.F.), Department of Neurology, University Hospital Schleswig-Holstein, Kiel; and Department of Neurology (K.W.), School of Medicine and Health Sciences-European Medical School, University Oldenburg and Research Center Neurosensory Science, Carl von Ossietzky University, Oldenburg, Germany.
| |
Collapse
|
9
|
Kaptan H, Çakmur R. Technical Case Report of Deep Brain Stimulation: Is it Possible Single Electrode Reach to Both of Subthalamic Nucleus and Ventral Intermediate Nucleus in One Stage? Open Access Maced J Med Sci 2018; 6:659-662. [PMID: 29731935 PMCID: PMC5927498 DOI: 10.3889/oamjms.2018.137] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2017] [Revised: 02/20/2018] [Accepted: 02/28/2018] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND: The primary target of this operation is Ventral Intermediate Nucleus (VIM); however VIM - Subthalamic Nucleus (STN) were tried to be reached with one electrode, adjusting the angle well, the coronal section; medial of VIM can partially reach the STN. Using the properties of the electrode; we believe we could act on a wide area. METHODS: An analysis was performed on one patient who underwent VIM Deep Brain Stimulation (DBS) in 3 periods (pre – peri - post-operation). RESULTS: A 53 – year - old woman diagnosed with Parkinson’s disease 8 years earlier including symptoms of severe tremor on the right than left underwent bilateral DBS VIM. Obtaining a satisfactory improvement of tremor, the patient did well, and postoperative complications were not observed. The patient was discharged from hospital on postoperative thirty day CONCLUSIONS: It is certain that more research and experience are needed. However, we believe that the two targets can reach the same point and the second operations for another target can be avoided.We believe that this initiative is advantageous and promising regarding patient and cost.
Collapse
Affiliation(s)
- Hülagu Kaptan
- Dokuz Eylül University, Medical Faculty, Izmir, Turkey
| | - Raif Çakmur
- Dokuz Eylül University, Medical School, Department of Neurology, İzmir, Turkey
| |
Collapse
|
10
|
Abstract
INTRODUCTION Essential tremor is the most common form of pathologic tremor. Surgical therapies disrupt tremorogenic oscillation in the cerebellothalamocortical pathway and are capable of abolishing severe tremor that is refractory to available pharmacotherapies. Surgical methods are raspidly improving and are the subject of this review. Areas covered: A PubMed search on 18 January 2018 using the query essential tremor AND surgery produced 839 abstracts. 379 papers were selected for review of the methods, efficacy, safety and expense of stereotactic deep brain stimulation (DBS), stereotactic radiosurgery (SRS), focused ultrasound (FUS) ablation, and radiofrequency ablation of the cerebellothalamocortical pathway. Expert commentary: DBS and SRS, FUS and radiofrequency ablations are capable of reducing upper extremity tremor by more than 80% and are far more effective than any available drug. The main research questions at this time are: 1) the relative safety, efficacy, and expense of DBS, SRS, and FUS performed unilaterally and bilaterally; 2) the relative safety and efficacy of thalamic versus subthalamic targeting; 3) the relative safety and efficacy of atlas-based versus direct imaging tractography-based anatomical targeting; and 4) the need for intraoperative microelectrode recordings and macroelectrode stimulation in awake patients to identify the optimum anatomical target. Randomized controlled trials are needed.
Collapse
Affiliation(s)
- Rodger J Elble
- a Neuroscience Institute , Southern Illinois University School of Medicine , Springfield , Illinois , USA
| | - Ludy Shih
- b Department of Neurology , Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , Massachusetts USA
| | - Jeffrey W Cozzens
- a Neuroscience Institute , Southern Illinois University School of Medicine , Springfield , Illinois , USA
| |
Collapse
|
11
|
Alomar S, King NKK, Tam J, Bari AA, Hamani C, Lozano AM. Speech and language adverse effects after thalamotomy and deep brain stimulation in patients with movement disorders: A meta-analysis. Mov Disord 2018; 32:53-63. [PMID: 28124434 DOI: 10.1002/mds.26924] [Citation(s) in RCA: 64] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Revised: 12/22/2016] [Accepted: 12/23/2016] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND The thalamus has been a surgical target for the treatment of various movement disorders. Commonly used therapeutic modalities include ablative and nonablative procedures. A major clinical side effect of thalamic surgery is the appearance of speech problems. OBJECTIVE This review summarizes the data on the development of speech problems after thalamic surgery. METHODS A systematic review and meta-analysis was performed using nine databases, including Medline, Web of Science, and Cochrane Library. We also checked for articles by searching citing and cited articles. We retrieved studies between 1960 and September 2014. RESULTS Of a total of 2,320 patients, 19.8% (confidence interval: 14.8-25.9) had speech difficulty after thalamotomy. Speech difficulty occurred in 15% (confidence interval: 9.8-22.2) of those treated with a unilaterally and 40.6% (confidence interval: 29.5-52.8) of those treated bilaterally. Speech impairment was noticed 2- to 3-fold more commonly after left-sided procedures (40.7% vs. 15.2%). Of the 572 patients that underwent DBS, 19.4% (confidence interval: 13.1-27.8) experienced speech difficulty. Subgroup analysis revealed that this complication occurs in 10.2% (confidence interval: 7.4-13.9) of patients treated unilaterally and 34.6% (confidence interval: 21.6-50.4) treated bilaterally. After thalamotomy, the risk was higher in Parkinson's patients compared to patients with essential tremor: 19.8% versus 4.5% in the unilateral group and 42.5% versus 13.9% in the bilateral group. After DBS, this rate was higher in essential tremor patients. CONCLUSION Both lesioning and stimulation thalamic surgery produce adverse effects on speech. Left-sided and bilateral procedures are approximately 3-fold more likely to cause speech difficulty. This effect was higher after thalamotomy compared to DBS. In the thalamotomy group, the risk was higher in Parkinson's patients, whereas in the DBS group it was higher in patients with essential tremor. Understanding the pathophysiology of speech disturbance after thalamic procedures is a priority. © 2017 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Soha Alomar
- King Abdulaziz University, Department of Surgery, Division of Neurosurgery, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.,University of Toronto, Department of Surgery, Division of Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada
| | - Nicolas K K King
- University of Toronto, Department of Surgery, Division of Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada.,Department of Neurosurgery, National Neuroscience Institute, Singapore
| | - Joseph Tam
- University of Toronto, Department of Surgery, Division of Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada
| | - Ausaf A Bari
- University of California Los Angeles, Department of Neurosurgery, Los Angeles, California, USA
| | - Clement Hamani
- University of Toronto, Department of Surgery, Division of Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada
| | - Andres M Lozano
- University of Toronto, Department of Surgery, Division of Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada
| |
Collapse
|
12
|
Improvement of Advanced Parkinson's Disease Manifestations with Deep Brain Stimulation of the Subthalamic Nucleus: A Single Institution Experience. Brain Sci 2016; 6:brainsci6040058. [PMID: 27983589 PMCID: PMC5187572 DOI: 10.3390/brainsci6040058] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Revised: 12/03/2016] [Accepted: 12/05/2016] [Indexed: 11/26/2022] Open
Abstract
We present our experience at the University of Illinois at Chicago (UIC) in deep brain stimulation (DBS) of the subthalamic nucleus (STN), describing our surgical technique, and reporting our clinical results, and morbidities. Twenty patients with advanced Parkinson’s disease (PD) who underwent bilateral STN-DBS were studied. Patients were assessed preoperatively and followed up for one year using the Unified Parkinson’s Disease Rating Scale (UPDRS) in “on” and “off” medication and “on” and “off” stimulation conditions. At one-year follow-up, we calculated significant improvement in all the motor aspects of PD (UPDRS III) and in activities of daily living (UPDRS II) in the “off” medication state. The “off” medication UPDRS improved by 49.3%, tremors improved by 81.6%, rigidity improved by 50.0%, and bradykinesia improved by 39.3%. The “off” medication UPDRS II scores improved by 73.8%. The Levodopa equivalent daily dose was reduced by 54.1%. The UPDRS IVa score (dyskinesia) was reduced by 65.1%. The UPDRS IVb score (motor fluctuation) was reduced by 48.6%. Deep brain stimulation of the STN improves the cardinal motor manifestations of the idiopathic PD. It also improves activities of daily living, and reduces medication-induced complications.
Collapse
|
13
|
Elias WJ, Lipsman N, Ondo WG, Ghanouni P, Kim YG, Lee W, Schwartz M, Hynynen K, Lozano AM, Shah BB, Huss D, Dallapiazza RF, Gwinn R, Witt J, Ro S, Eisenberg HM, Fishman PS, Gandhi D, Halpern CH, Chuang R, Butts Pauly K, Tierney TS, Hayes MT, Cosgrove GR, Yamaguchi T, Abe K, Taira T, Chang JW. A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. N Engl J Med 2016; 375:730-9. [PMID: 27557301 DOI: 10.1056/nejmoa1600159] [Citation(s) in RCA: 659] [Impact Index Per Article: 82.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Uncontrolled pilot studies have suggested the efficacy of focused ultrasound thalamotomy with magnetic resonance imaging (MRI) guidance for the treatment of essential tremor. METHODS We enrolled patients with moderate-to-severe essential tremor that had not responded to at least two trials of medical therapy and randomly assigned them in a 3:1 ratio to undergo unilateral focused ultrasound thalamotomy or a sham procedure. The Clinical Rating Scale for Tremor and the Quality of Life in Essential Tremor Questionnaire were administered at baseline and at 1, 3, 6, and 12 months. Tremor assessments were videotaped and rated by an independent group of neurologists who were unaware of the treatment assignments. The primary outcome was the between-group difference in the change from baseline to 3 months in hand tremor, rated on a 32-point scale (with higher scores indicating more severe tremor). After 3 months, patients in the sham-procedure group could cross over to active treatment (the open-label extension cohort). RESULTS Seventy-six patients were included in the analysis. Hand-tremor scores improved more after focused ultrasound thalamotomy (from 18.1 points at baseline to 9.6 at 3 months) than after the sham procedure (from 16.0 to 15.8 points); the between-group difference in the mean change was 8.3 points (95% confidence interval [CI], 5.9 to 10.7; P<0.001). The improvement in the thalamotomy group was maintained at 12 months (change from baseline, 7.2 points; 95% CI, 6.1 to 8.3). Secondary outcome measures assessing disability and quality of life also improved with active treatment (the blinded thalamotomy cohort)as compared with the sham procedure (P<0.001 for both comparisons). Adverse events in the thalamotomy group included gait disturbance in 36% of patients and paresthesias or numbness in 38%; these adverse events persisted at 12 months in 9% and 14% of patients, respectively. CONCLUSIONS MRI-guided focused ultrasound thalamotomy reduced hand tremor in patients with essential tremor. Side effects included sensory and gait disturbances. (Funded by InSightec and others; ClinicalTrials.gov number, NCT01827904.).
Collapse
Affiliation(s)
- W Jeffrey Elias
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Nir Lipsman
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - William G Ondo
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Pejman Ghanouni
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Young G Kim
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Wonhee Lee
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Michael Schwartz
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Kullervo Hynynen
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Andres M Lozano
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Binit B Shah
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Diane Huss
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Robert F Dallapiazza
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Ryder Gwinn
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Jennifer Witt
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Susie Ro
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Howard M Eisenberg
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Paul S Fishman
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Dheeraj Gandhi
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Casey H Halpern
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Rosalind Chuang
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Kim Butts Pauly
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Travis S Tierney
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Michael T Hayes
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - G Rees Cosgrove
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Toshio Yamaguchi
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Keiichi Abe
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Takaomi Taira
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Jin W Chang
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| |
Collapse
|
14
|
Picillo M, Lozano AM, Kou N, Munhoz RP, Fasano A. Programming Deep Brain Stimulation for Tremor and Dystonia: The Toronto Western Hospital Algorithms. Brain Stimul 2016; 9:438-452. [DOI: 10.1016/j.brs.2016.02.003] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Revised: 01/02/2016] [Accepted: 02/03/2016] [Indexed: 10/22/2022] Open
|
15
|
Said N, Elias WJ, Raghavan P, Cupino A, Tustison N, Frysinger R, Patrie J, Xin W, Wintermark M. Correlation of diffusion tensor tractography and intraoperative macrostimulation during deep brain stimulation for Parkinson disease. J Neurosurg 2014; 121:929-35. [DOI: 10.3171/2014.6.jns131673] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Object
The purpose of this study was to investigate whether diffusion tensor imaging (DTI) of the corticospinal tract (CST) is a reliable surrogate for intraoperative macrostimulation through the deep brain stimulation (DBS) leads. The authors hypothesized that the distance on MRI from the DBS lead to the CST as determined by DTI would correlate with intraoperative motor thresholds from macrostimulations through the same DBS lead.
Methods
The authors retrospectively reviewed pre- and postoperative MRI studies and intraoperative macrostimulation recordings in 17 patients with Parkinson disease (PD) treated by DBS stimulation. Preoperative DTI tractography of the CST was coregistered with postoperative MRI studies showing the position of the DBS leads. The shortest distance and the angle from each contact of each DBS lead to the CST was automatically calculated using software-based analysis. The distance measurements calculated for each contact were evaluated with respect to the intraoperative voltage thresholds that elicited a motor response at each contact.
Results
There was a nonsignificant trend for voltage thresholds to increase when the distances between the DBS leads and the CST increased. There was a significant correlation between the angle and the voltage, but the correlation was weak (coefficient of correlation [R] = 0.36).
Conclusions
Caution needs to be exercised when using DTI tractography information to guide DBS lead placement in patients with PD. Further studies are needed to compare DTI tractography measurements with other approaches such as microelectrode recordings and conventional intraoperative MRI–guided placement of DBS leads.
Collapse
Affiliation(s)
| | | | | | - Alan Cupino
- 1Departments of Radiology, Neuroradiology Division
| | | | | | - James Patrie
- 3Public Health Sciences, University of Virginia, Charlottesville, Virginia; and
| | - Wenjun Xin
- 3Public Health Sciences, University of Virginia, Charlottesville, Virginia; and
| | - Max Wintermark
- 1Departments of Radiology, Neuroradiology Division
- 4Department of Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| |
Collapse
|
16
|
Lipsman N, Mainprize TG, Schwartz ML, Hynynen K, Lozano AM. Intracranial applications of magnetic resonance-guided focused ultrasound. Neurotherapeutics 2014; 11:593-605. [PMID: 24850310 PMCID: PMC4121456 DOI: 10.1007/s13311-014-0281-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
The ability to focus acoustic energy through the intact skull on to targets millimeters in size represents an important milestone in the development of neurotherapeutics. Magnetic resonance-guided focused ultrasound (MRgFUS) is a novel, noninvasive method, which--under real-time imaging and thermographic guidance--can be used to generate focal intracranial thermal ablative lesions and disrupt the blood-brain barrier. An established treatment for bone metastases, uterine fibroids, and breast lesions, MRgFUS has now been proposed as an alternative to open neurosurgical procedures for a wide variety of indications. Studies investigating intracranial MRgFUS range from small animal preclinical experiments to large, late-phase randomized trials that span the clinical spectrum from movement disorders, to vascular, oncologic, and psychiatric applications. We review the principles of MRgFUS and its use for brain-based disorders, and outline future directions for this promising technology.
Collapse
Affiliation(s)
- Nir Lipsman
- Division of Neurosurgery, University Health Network, University of Toronto, 399 Bathurst Street, 4W-431, Toronoto, M5T 2S8, Canada,
| | | | | | | | | |
Collapse
|
17
|
Abstract
Movement disorders remain the primary indication for the use of intracranial neurostimulation techniques. This review will discuss the history of this technology as well as the mechanisms of action, current clinical indications, and future prospects for the treatment of movement disorders.
Collapse
Affiliation(s)
- Joshua M Rosenow
- Department of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | | | | |
Collapse
|
18
|
Zappia M, Albanese A, Bruno E, Colosimo C, Filippini G, Martinelli P, Nicoletti A, Quattrocchi G. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. J Neurol 2012; 260:714-40. [DOI: 10.1007/s00415-012-6628-x] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2012] [Revised: 07/12/2012] [Accepted: 07/12/2012] [Indexed: 10/28/2022]
|
19
|
Kádár E, Lim LW, Carreras G, Genís D, Temel Y, Huguet G. High-frequency stimulation of the ventrolateral thalamus regulates gene expression in hippocampus, motor cortex and caudate–putamen. Brain Res 2011; 1391:1-13. [DOI: 10.1016/j.brainres.2011.03.059] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2010] [Revised: 03/22/2011] [Accepted: 03/23/2011] [Indexed: 02/05/2023]
|
20
|
|
21
|
Nishio M, Korematsu K, Yoshioka S, Nagai Y, Maruo T, Ushio Y, Kaji R, Goto S. Long-term suppression of tremor by deep brain stimulation of the ventral intermediate nucleus of the thalamus combined with pallidotomy in hemiparkinsonian patients. J Clin Neurosci 2009; 16:1489-91. [PMID: 19628395 DOI: 10.1016/j.jocn.2009.02.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2008] [Revised: 02/02/2009] [Accepted: 02/03/2009] [Indexed: 11/24/2022]
Abstract
Deep brain stimulation (DBS) of the ventral intermediate nucleus of the thalamus (VIM) is a powerful surgical option in the treatment of tremor-predominant Parkinson's disease. However, its therapeutic efficacy depends on the tremor distribution. DBS is highly efficient in relief of distal appendicular tremor but not other types of tremor. Also, it is generally thought that DBS of the VIM has no significant beneficial effects on other motor symptoms of Parkinson's disease. We report two hemiparkinsonian patients, in whom unilateral VIM DBS combined with posteroventral pallidotomy produced long-lasting suppression of not only hand tremor, but also leg or jaw tremor and other motor symptoms.
Collapse
Affiliation(s)
- Masami Nishio
- Department of Neurosurgery, Otemae Hospital, Osaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Rezai AR, Machado AG, Deogaonkar M, Azmi H, Kubu C, Boulis NM. Surgery for movement disorders. Neurosurgery 2008; 62 Suppl 2:809-38; discussion 838-9. [PMID: 18596424 DOI: 10.1227/01.neu.0000316285.52865.53] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Movement disorders, such as Parkinson's disease, tremor, and dystonia, are among the most common neurological conditions and affect millions of patients. Although medications are the mainstay of therapy for movement disorders, neurosurgery has played an important role in their management for the past 50 years. Surgery is now a viable and safe option for patients with medically intractable Parkinson's disease, essential tremor, and dystonia. In this article, we provide a review of the history, neurocircuitry, indication, technical aspects, outcomes, complications, and emerging neurosurgical approaches for the treatment of movement disorders.
Collapse
Affiliation(s)
- Ali R Rezai
- Center for Neurological Restoration, and Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio 44122, USA.
| | | | | | | | | | | |
Collapse
|
23
|
Abstract
Deep brain stimulation (DBS) has been used to treat various tremor disorders for several decades. Medication-resistant, disabling essential tremor (ET) is the most common tremor disorder treated with DBS. The treatment has been consistently reported to result in significant benefit in upper extremity, as well as head and voice tremor, all of which were improved more dramatically with bilateral procedures. These benefits have been demonstrated to be sustained for up to 7 years. DBS has also been shown to be beneficial for the tremor associated with multiple sclerosis and post-traumatic tremor; however, fewer cases have been reported and the benefit is less consistent, less dramatic, and more transient than that seen with ET. The ventral intermediate nucleus of the thalamus is the most common DBS target for tremor disorders, but more recent studies have demonstrated benefits in tremor from DBS of the subthalamic area, primarily the zona incerta. Surgical complications are relatively uncommon and are generally less frequent than those seen with thalamotomy. Stimulation-related effects are usually mild and resolve with adjustment of stimulation parameters. DBS is thus a relatively safe and effective treatment for tremor disorders, particularly for medication-resistant, disabling ET, but may also have some role in medication-resistant, disabling tremor associated with multiple sclerosis and traumatic head injury.
Collapse
Affiliation(s)
- Kelly E Lyons
- Parkinson's Disease and Movement Disorder Center, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA.
| | | |
Collapse
|
24
|
Hooper AK, Okun MS, Foote KD, Fernandez HH, Jacobson C, Zeilman P, Romrell J, Rodriguez RL. Clinical cases where lesion therapy was chosen over deep brain stimulation. Stereotact Funct Neurosurg 2008; 86:147-52. [PMID: 18334856 DOI: 10.1159/000120426] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Deep brain stimulation (DBS) surgery has become the gold standard for treatment of select refractory cases of Parkinson disease and essential tremor. Despite the usefulness of DBS surgery in many cases, there remain situations where lesion therapy (subthalamotomy, pallidotomy or thalamotomy) may provide a reasonable alternative to DBS. We reviewed the University of Florida Institutional Review Board-approved database for movement disorders surgery and identified 286 DBS leads placed in 189 patients as well as 4 additional patients who had lesion therapy. In these 4 cases we reviewed the clinical presentations that resulted in a multidisciplinary team opting for lesion therapy over DBS. Lesion therapy represents a viable alternative and has several important advantages, including a decreased need for access to specialists and clinical follow-up, improved affordability, and a lower infection risk.
Collapse
Affiliation(s)
- Amanda K Hooper
- University of Florida, Movement Disorders Center, Gainesville, FL 32601, USA.
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
BACKGROUND Deep brain stimulation (DBS) has emerged as an important treatment for medication refractory movement and neuropsychiatric disorders. General neurologists and even general practitioners may be called upon to screen potential candidates for DBS. The patient selection process plays an important role in this procedure. REVIEW SUMMARY In this article, we discuss "pearls" for the clinician who may be called upon to identify appropriate candidates for DBS. Additionally, we will discuss the important points that should be considered when referring patients for surgical intervention. CONCLUSION Diagnosis, response to levodopa, cognitive status, psychiatric status, access to care, and patient expectations are all essential elements of the patient selection process for DBS. These areas must be adequately addressed prior to any surgical procedure.
Collapse
Affiliation(s)
- Ramon L Rodriguez
- Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, Florida, USA.
| | | | | | | |
Collapse
|
26
|
Deuschl G, Herzog J, Kleiner-Fisman G, Kubu C, Lozano AM, Lyons KE, Rodriguez-Oroz MC, Tamma F, Tröster AI, Vitek JL, Volkmann J, Voon V. Deep brain stimulation: Postoperative issues. Mov Disord 2006; 21 Suppl 14:S219-37. [PMID: 16810719 DOI: 10.1002/mds.20957] [Citation(s) in RCA: 199] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Numerous factors need to be taken into account when managing a patient with Parkinson's disease (PD) after deep brain stimulation (DBS). Questions such as when to begin programming, how to conduct a programming screen, how to assess the effects of programming, and how to titrate stimulation and medication for each of the targeted sites need to be addressed. Follow-up care should be determined, including patient adjustments of stimulation, timing of follow-up visits and telephone contact with the patient, and stimulation and medication conditions during the follow-up assessments. A management plan for problems that can arise after DBS such as weight gain, dyskinesia, axial symptoms, speech dysfunction, muscle contractions, paresthesia, eyelid, ocular and visual disturbances, and behavioral and cognitive problems should be developed. Long-term complications such as infection or erosion, loss of effect, intermittent stimulation, tolerance, and pain or discomfort can develop and need to be managed. Other factors that need consideration are social and job-related factors, development of dementia, general medical issues, and lifestyle changes. This report from the Consensus on Deep Brain Stimulation for Parkinson's Disease, a project commissioned by the Congress of Neurological Surgeons and the Movement Disorder Society, outlines answers to a series of questions developed to address all aspects of DBS postoperative management and decision-making with a systematic overview of the literature (until mid-2004) and by the expert opinion of the authors. The report has been endorsed by the Scientific Issues Committee of the Movement Disorder Society and the American Society of Stereotactic and Functional Neurosurgery.
Collapse
Affiliation(s)
- Günther Deuschl
- Department of Neurology, Christian-Albrechts-Universität Kiel, Kiel, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Putzke JD, Uitti RJ, Obwegeser AA, Wszolek ZK, Wharen RE. Bilateral thalamic deep brain stimulation: midline tremor control. J Neurol Neurosurg Psychiatry 2005; 76:684-90. [PMID: 15834027 PMCID: PMC1739619 DOI: 10.1136/jnnp.2004.041434] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVES To determine the efficacy of bilateral deep brain stimulation (DBS) for management of midline tremor (head, voice, tongue, trunk) in patients with essential tremor. DESIGN Prospective assessment of tremor at baseline (presurgical), and postoperatively at 1, 3, and 12 months, and annually thereafter. METHODS A clinical series of 22 individuals undergoing staged, bilateral DBS for treatment of essential tremor. The tremor rating scale was the primary outcome measure. RESULTS Midline tremor showed significant improvement with stimulation "on" at nearly every postoperative interval when compared with stimulation "off" and with baseline tremor. Bilateral stimulation was associated with a significant incremental improvement in midline tremor control compared with unilateral stimulation: average "stimulation on" percentage change in midline tremor from the unilateral to bilateral period was 81%. Head and voice tremor showed the most consistent improvement. Among those requiring a change in stimulation parameters because of side effects, dysarthria, disequilibrium, motor disturbances, and paraesthesiae were the most common. Dysarthria was more common with bilateral (n = 6; 27%) than with unilateral (n = 0) stimulation. Stimulation parameters remained largely unchanged after the first three months. Nine of 44 leads placed (20%) required subsequent repositioning or replacement. CONCLUSIONS Unilateral thalamic stimulation significantly improves midline tremor, and subsequent bilateral thalamic stimulation offers an additional incremental improvement in midline tremor control.
Collapse
Affiliation(s)
- J D Putzke
- Department of Neurology, Mayo Clinic Jacksonville, FL 32224, USA
| | | | | | | | | |
Collapse
|
28
|
Gorgulho A, De Salles AAF, Frighetto L, Behnke E. Incidence of hemorrhage associated with electrophysiological studies performed using macroelectrodes and microelectrodes in functional neurosurgery. J Neurosurg 2005; 102:888-96. [PMID: 15926715 DOI: 10.3171/jns.2005.102.5.0888] [Citation(s) in RCA: 131] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Object. The goal of this study was to analyze the incidence of intracranial bleeding in patients who underwent procedures guided by microelectrode recording (MER) rather than by macroelectrode stimulation alone.
Methods. Between March 1994 and July 2001, 178 patients underwent 248 functional neurosurgical procedures performed by the same team at the University of California at Los Angeles. The procedures included pallidotomy (122 patients), thalamotomy (19 patients), and implantation of deep brain stimulation electrodes in the subthalamic nucleus (36 patients), globus pallidus internus (17 patients), and ventralis intermedius nucleus (54 patients). One hundred forty-four procedures involved macroelectrode stimulation and 104 involved MER. Groups were analyzed according to the presence of arterial hypertension, MER or macroelectrode stimulation use, and occurrence of hemorrhage. Nineteen patients with arterial hypertension underwent 28 surgical procedures.
Five cases of hemorrhage (2.02%) occurred. One patient presented with hemiparesis and dysphasia but no surgery was required. The incidence of hemorrhage in patients in whom MER was performed was 2.9%, whereas the incidence in patients in whom MER was not used was 1.4% (p = 0.6529). Bleeding occurred in 10.71% of patients with hypertension and 0.91% of those who were nonhypertensive (p = 0.0111). Among the 104 patients in whom MER was performed, 12 had hypertension. Bleeding occurred in two (16.67%) of these 12 patients. An increased incidence of bleeding in hypertensive patients who underwent MER (p = 0.034) was noticed when compared with nonhypertensive patients who underwent MER. A higher number of electrode passes through the parenchyma was observed when MER was used (p = 0.0001). A positive trend between the occurrence of hemorrhage and multiple passes was noticed.
Conclusions. Based on the data the authors suggest that a higher incidence of hemorrhage occurs in hypertensive patients, and a higher incidence as well in hypertensive patients who underwent MER rather than macroeletrode stimulation. Special attention should be given to MER use in hypertensive patients and particular attention should be made to multiple passes.
Collapse
Affiliation(s)
- Alessandra Gorgulho
- Division of Neurosurgery, University of California at Los Angeles, California, USA
| | | | | | | |
Collapse
|
29
|
Putzke JD, Wharen RE, Obwegeser AA, Wszolek ZK, Lucas JA, Turk MF, Uitti RJ. Thalamic deep brain stimulation for essential tremor: recommendations for long-term outcome analysis. Can J Neurol Sci 2004; 31:333-42. [PMID: 15376477 DOI: 10.1017/s0317167100003413] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVES Determine the efficacy of thalamic deep brain stimulation (DBS) for tremor control among individuals with essential tremor (ET). METHODS A clinical series of 52 consecutive individuals undergoing placement of a DBS system for treatment of ET completed an unblinded battery of subjective and objective measures at postoperative intervals of one, three, and 12 months, and annually thereafter up to three years. The assessment battery included measures of tremor and activities of daily living. RESULTS Both subjective and objective measures showed that stimulation was associated with significant improvement at nearly every postoperative interval as compared to pre-operative and stimulation 'off' ratings of activities of daily living functioning, midline tremor, contralateral upper extremity tremor, and contralateral lower extremity tremor. Ipsilateral tremor showed some improvement with stimulation, but only within the first three months. Trend analysis showed stable tremor control. Stimulation settings remained largely unchanged after the first three months. Dysarthria was more common among those with bilateral stimulation. A range of missing data estimation methods were performed, and subsequent analyses corroborated the main findings of the study. CONCLUSION Thalamic DBS is generally a well-tolerated and effective treatment for ET. Methodological and analytical recommendations are provided for the evaluation of long-term outcome.
Collapse
Affiliation(s)
- J D Putzke
- Department of Neurology, Mayo Clinic, Jacksonville, FL 32224 , USA
| | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
Throughout the past decade, there has been a marked increase in surgical therapies, primarily deep brain stimulation (DBS), for the treatment of advanced Parkinson's disease (PD). DBS of the thalamus has been shown to be effective in reducing parkinsonian tremor; however, it is not the treatment of choice for PD given the progression of other symptoms such as rigidity and bradykinesia. Stimulation of the globus pallidus or the subthalamic nucleus is safe and efficacious in the long-term treatment of all cardinal symptoms of PD, and they are currently the surgeries of choice. Serious adverse events with DBS can occur in 1% to 2% of patients, infection in 5% to 8% of patients, and hardware complications in approximately 25% of patients. Complications associated with DBS are related to the experience of the surgical center. Referring physicians and patients should be aware of the number of surgical procedures and complication rates of any prospective surgical center.
Collapse
Affiliation(s)
- Kelly E Lyons
- Department of Neurology, University of Kansas Medical Center, 3599 Rainbow Boulevard, Mailstop 2012, Kansas City, KS 66160, USA.
| | | |
Collapse
|
31
|
Mohs Micrographic Surgery in a Patient with a Deep Brain Stimulator. Dermatol Surg 2004. [DOI: 10.1097/00042728-200407000-00012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Martinelli PT, Schulze KE, Nelson BR. Mohs Micrographic Surgery in a Patient with a Deep Brain Stimulator: A Review of the Literature on Implantable Electrical Devices. Dermatol Surg 2004; 30:1021-30. [PMID: 15209793 DOI: 10.1111/j.1524-4725.2004.30308.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Implantable electrical devices are becoming increasingly common in the patient population presenting for Mohs micrographic surgery. In addition to understanding the potential intraoperative complications with implantable cardioverter-defibrillators and pacemakers, the Mohs surgeon needs to be aware of the relatively new treatment of movement disorders using implanted deep brain stimulators. OBJECTIVE We present only the second reported case of Mohs surgery in a patient with a deep brain stimulator. In an attempt to help minimize adverse events during a procedure, we review the more commonly encountered electrical devices as well as the newer deep brain stimulators. We provide guidelines for the avoidance of electromagnetic interference during an electrosurgical procedure. METHODS This 76-year-old patient with Parkinson's disease and an implanted deep brain stimulator underwent Mohs surgery for excision of a squamous cell carcinoma on the ear. In an attempt to minimize electromagnetic interference with his implanted device, hemostasis was obtained with the aid of a battery-operated heat-generating handheld electrocautery device. RESULTS The patient tolerated the procedure well without complications or reports of discomfort. CONCLUSION Patients with implanted electrical devices are subject to electromagnetic interference during an electrosurgical procedure. Care must be taken in this expanding patient population during a Mohs surgical procedure.
Collapse
Affiliation(s)
- Paul T Martinelli
- Department of Dermatology, Baylor College of Medicine, Houston, Texas 77030, USA.
| | | | | |
Collapse
|
33
|
Kishima H, Poyot T, Bloch J, Dauguet J, Condé F, Dollé F, Hinnen F, Pralong W, Palfi S, Déglon N, Aebischer P, Hantraye P. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol Dis 2004; 16:428-39. [PMID: 15193299 DOI: 10.1016/j.nbd.2004.03.012] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2003] [Revised: 03/01/2004] [Accepted: 03/22/2004] [Indexed: 10/26/2022] Open
Abstract
Glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophic factor with restorative effects in a variety of rodent and primate models of Parkinson's disease (PD), could be of therapeutic value to PD. In this study, we show that intraventricular chronic infusion of low doses of GDNF using encapsulated genetically engineered C2C12 cells can exert: (1) transient recovery of motor deficits (hypokinesia); (2) significant protection of intrinsic striatal dopaminergic function in the immediate vicinity of the site of implantation of the capsule in the caudate nucleus, and (3) significant-long-lasting-neurotrophic properties at the nigral level with an increase volume of the cell bodies. These observations confirm the potent neurorestorative potential of GDNF in PD and the safety/efficacy of the encapsulation technology as a means to deliver in situ this neurotrophic cytokine even using an intraventricular approach.
Collapse
Affiliation(s)
- Haruhiko Kishima
- Research Associate Unit URA CEA CNRS 2210, Service Hospitalier Frédéric Joliot, Orsay, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Putzke JD, Wharen RE, Wszolek ZK, Turk MF, Strongosky AJ, Uitti RJ. Thalamic deep brain stimulation for tremor-predominant Parkinson's disease. Parkinsonism Relat Disord 2003; 10:81-8. [PMID: 14643997 DOI: 10.1016/j.parkreldis.2003.09.002] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVES Determine the long-term efficacy of thalamic deep brain stimulation (DBS) for treatment of tremor among individuals with tremor-predominant Parkinson's disease (PD).Design. Longitudinal, unblinded assessment of tremor and activities of daily living (ADL) at baseline (pre-surgical), and post-operative intervals of 1, 3, and 12 months, and annually thereafter up to 3 years. METHODS A clinical series of 19 individuals undergoing placement of a DBS system for treatment of PD-related tremor. A battery of subjective and objective measures of tremor was completed at planned pre- and post-operative intervals. RESULTS Stimulation was associated with significant improvement on subjective and objective measures of ADL performance, midline tremor, and contralateral upper and lower extremity tremor, including parkinsonian resting and action tremors, over the follow-up period. Ipsilateral tremor showed little or no effect of stimulation after the first 3 months. Antiparkinsonian medication use and stimulation parameters showed little or no change over the course of follow-up. About half (53%) of all individuals reported at least one side effect, generally mild, during the follow-up period, with paresthesias and dysarthria being the most common. A total of two leads required replacement due to (1) infection, and (2) adverse side effects (i.e. burning and tingling with stimulation). CONCLUSION DBS is associated with stable tremor control in PD. Side-effects are typically easily managed with stimulation adjustments, although in some cases lead replacement may be required.
Collapse
Affiliation(s)
- J D Putzke
- Department of Neurology, Davis Bldg E-8, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
| | | | | | | | | | | |
Collapse
|
35
|
Spiegel J, Fuss G, Backens M, Reith W, Magnus T, Becker G, Moringlane JR, Dillmann U. Transient dystonia following magnetic resonance imaging in a patient with deep brain stimulation electrodes for the treatment of Parkinson disease. Case report. J Neurosurg 2003; 99:772-4. [PMID: 14567615 DOI: 10.3171/jns.2003.99.4.0772] [Citation(s) in RCA: 109] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Data from previous studies have shown that magnetic resonance (MR) imaging of the head can be performed safely in patients with deep brain stimulators. The authors report on a 73-year-old patient with bilaterally implanted deep brain electrodes for the treatment of Parkinson disease, who exhibited dystonic and partially ballistic movements of the left leg immediately after an MR imaging session. Such dystonic or ballistic movements had not been previously observed in this patient. In the following months, this focal movement disorder resolved completely. This case demonstrates the possible risks of MR imaging in patients with deep brain stimulators.
Collapse
Affiliation(s)
- Jörg Spiegel
- Department of Neurology, Saarland University, Homburg/Saar, Germany
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Kiss ZHT, Wilkinson M, Krcek J, Suchowersky O, Hu B, Murphy WF, Hobson D, Tasker RR. Is the target for thalamic deep brain stimulation the same as for thalamotomy? Mov Disord 2003; 18:1169-75. [PMID: 14534922 DOI: 10.1002/mds.10524] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Deep brain stimulation (DBS) has virtually replaced thalamotomy for the treatment of essential tremor. It is thought that the site for DBS is the same as the optimal lesion site; however, this match has not been investigated previously. We sought to determine whether the location of thalamic DBS matched the site at which thalamotomy would be performed. Eleven patients who had detailed microelectrode recording and stimulation for placement of DBS electrodes and subsequent successful tremor control were analysed. An experienced surgeon, blinded to outcome and final electrode position, selected the ideal thalamotomy site based on the reconstructed maps obtained intraoperatively. When the site of long-term clinically used DBS and theoretical thalamotomy location was calculated in three-dimensional space and compared for each of the x, y, and z axes in stereotactic space, there was no significant difference in the mediolateral location of DBS and theoretical lesion site. There was also no difference between the theoretical lesion site and the placement of the tip of the electrode; however, the active electrodes used for chronic stimulation were significantly more anterior (P = 0.005) and dorsal (P = 0.034) to the ideal thalamotomy target. This mismatch may reflect the compromise required between adverse and beneficial effects with chronic stimulation, but it also suggests different mechanisms of effect of DBS and thalamotomy.
Collapse
Affiliation(s)
- Zelma H T Kiss
- Department of Clinical Neurosciences, University of Calgary, Foothills Hospital Calgary Health Region, Calgary, Alberta, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Anderson KE, Mullins J. Behavioral changes associated with deep brain stimulation surgery for Parkinson's disease. Curr Neurol Neurosci Rep 2003; 3:306-13. [PMID: 12930700 DOI: 10.1007/s11910-003-0007-z] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Evaluation for psychiatric and cognitive dysfunction is a crucial part of preoperative assessment for deep brain stimulation (DBS) surgery. All candidates for DBS should be treated for active psychiatric disorders, and the treatment team should also screen for past psychiatric history, which may predispose to postoperative psychiatric illness. A wide range of behavioral symptoms have been seen following DBS, including depression, hallucinations or true psychosis, mania, and impulsivity. Suicidal ideation should be treated aggressively. Cognitive changes may occur, but data are currently too limited to make predictions regarding subtle effects on cognition. However, patients with dementia may experience further decline in cognitive function following DBS.
Collapse
Affiliation(s)
- Karen E Anderson
- Division of Movement Disorders, Department of Neurology, University of Maryland School of Medicine, 22 South Greene Street, Room NW49A, Baltimore, MD 21201, USA.
| | | |
Collapse
|
38
|
Bryant JA, De Salles A, Cabatan C, Frysinger R, Behnke E, Bronstein J. The impact of thalamic stimulation on activities of daily living for essential tremor. SURGICAL NEUROLOGY 2003; 59:479-84; discussion 484-5. [PMID: 12826348 DOI: 10.1016/s0090-3019(03)00091-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Deep Brain Stimulation (DBS) of the ventro-intermedius nucleus of the thalamus is the treatment of choice for drug-refractory essential tremor (ET). This study evaluated the effectiveness of thalamic stimulation in improving the patient's quality of life through activities of daily living. METHODS Sixteen ET patients completed a health questionnaire, the "Tremor Activities of Daily Living Scale" (TADLS) measured by the patient, a 10-item subset of the TADLS measured by the clinician, and the Fahn-Tolosa-Marin tremor rating scale (TRS). Each patient was evaluated with the stimulator on and off with the average evaluation occurring 13 months after surgery. Additionally, improvements on the TADLS were compared to electrode positioning on the axial plane and stimulation parameters. RESULTS There was a 44.0% improvement in the patient-rated TADLS, a 45.2% improvement in the clinician-rated TADLS, and a 33.9% improvement in the TRS. The average electrode location was 5.65 mm anterior to the posterior commissure (AC-PC), 13.4 mm lateral from the midline, and 2.0 mm below the AC-PC line. The average stimulation parameters were 2.74 Volts, 160 Hertz, and 119 microsec. There was no correlation between improvements on the TADLS, electrode location, and stimulation parameters. Of the 16 patients, 10 patients would repeat the surgery, two were unsure, and four would not repeat the surgery. CONCLUSIONS Tremor is significantly controlled with DBS and activities of daily living are highly correlated with patient satisfaction. The degree of improvement in the four patients who would not repeat the surgery was outweighed by the negative factors associated with the surgery.
Collapse
|
39
|
Terao T, Takahashi H, Yokochi F, Taniguchi M, Okiyama R, Hamada I. Hemorrhagic complication of stereotactic surgery in patients with movement disorders. J Neurosurg 2003; 98:1241-6. [PMID: 12816271 DOI: 10.3171/jns.2003.98.6.1241] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECT Small, asymptomatic hemorrhages are easier to detect during stereotactic surgery when magnetic resonance (MR) imaging is used for targeting rather than when traditional approaches, such as ventriculography, are performed with contrast material. In the present study the authors examined the actual incidence of intraoperative hemorrhages in patients with movement disorders who had undergone MR imaging-targeted surgery, microelectrode recording (MER)-guided implantation of deep brain stimulation (DBS) electrodes, or radiofrequency-induced coagulation surgery performed. METHODS Ninety-six consecutive patients underwent a total of 116 stereotactic operations for movement disorders (57 operations for radiofrequency-induced coagulation and 59 for DBS electrode implantation) between January 1998 and November 2002. The authors investigated the correlation between hemorrhages and other factors including the location of the hemorrhage and the type of surgery performed. Postoperative computerized tomography scans demonstrated the occurrence of intraoperative hemorrhages at 12 locations during 11 procedures (9.5% of all procedures). Nine hemorrhages occurred during 57 coagulation operations (15.8%). Within this group, the frequency of hemorrhages was highest during thalamotomy (five [21.7%] of 23 procedures) and lower during pallidotomy (four [11.8%] of 34 procedures). In contrast, only two intraventricular hemorrhages developed during 59 operations in which DBS electrodes were implanted (3.4%). In no case was hemorrhage detected in the main DBS target, that is, the subthalamic nucleus. CONCLUSIONS When small, asymptomatic hemorrhages were included in the estimation, the actual rate of hemorrhage was higher than that previously reported. Judging from the incidence of hemorrhage during coagulation and DBS surgeries, the authors suggest that the heat induced by coagulation may play a larger role than microelectrode penetration in the development of hemorrhage.
Collapse
Affiliation(s)
- Tohru Terao
- Department of Neurosurgery, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.
| | | | | | | | | | | |
Collapse
|
40
|
Abstract
Essential tremor (ET) is the most prevalent tremor syndrome. It commonly affects the hands, head, voice, and other body parts. Appropriate management begins with correct diagnosis. Primidone and propranolol are the first-line medications for the treatment for ET, but several other medications may also provide benefit. In patients with medically refractory tremor, alternative therapies, including surgery or injections of botulinum toxin, may be considered.
Collapse
Affiliation(s)
- Theresa A Zesiewicz
- Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Harborside Medical Tower, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA.
| | | | | |
Collapse
|
41
|
Nasser JA, Falavigna A, Alaminos A, Bonatelli ADP, Ferraz F. Estimulação cerebral contínua (DBS) talâmica para controle do tremor. ARQUIVOS DE NEURO-PSIQUIATRIA 2002. [DOI: 10.1590/s0004-282x2002000300017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJETIVO: Apresentamos resultados da estimulação contínua do núcleo ventral intermédio (VIM) talâmico para o controle do tremor. MÉTODO: Quatro pacientes foram selecionados no período de outubro de 1999 a janeiro de 2001 com tremor incapacitante refratário à farmacoterapia. Dois pacientes apresentavam tremor essencial (TE) bilateral e 2 pacientes tremor de repouso por doença de Parkinson (DP), um à direita e outro à esquerda. Após avaliação sistemática, foram submetidos ao implante de eletrodo talâmico, modelo DBS 3387(Medtronic), para estimulação cerebral profunda (ECP) com alta frequência, sendo este bilateral nos casos de TE e unilateral nos casos com tremor por DP. RESULTADOS: Os pacientes tiveram seu seguimente clínico até o presente, com média de 12 meses, sendo observada a eficácia da estimulação do núcleo VIM no controle dos disparos das células do tremor. As complicações temporárias do tipo parestesias, disartrias e discreto aumento do tônus foram revertidas após o ajuste dos parâmetros de estimulação. CONCLUSÃO: Os resultados confirmam os achados da literatura, de que a estimulação talâmica é excelente opção terapêutica no tratamento do tremor, havendo possibilidade de estimulação talâmica bilateral simultânea com segurança.
Collapse
Affiliation(s)
- José Augusto Nasser
- Hospital Pró-Cardíaco; Estereolife, Neurocirurgia Funcional e Estereotáxica; Universidade Estácio de Sá, Brasil; Universidade Federal de São Paulo, Brasil
| | - Asdrubal Falavigna
- Hospital Pró-Cardíaco; Estereolife, Neurocirurgia Funcional e Estereotáxica; Universidade Estácio de Sá, Brasil
| | - Armando Alaminos
- Hospital Pró-Cardíaco; Estereolife, Neurocirurgia Funcional e Estereotáxica; Universidade Estácio de Sá, Brasil
| | | | | |
Collapse
|
42
|
Abstract
Patients with nonparkinsonian tremors are the second largest group treated with functional neurosurgery. We summarize the present pathophysiological knowledge of these conditions. Essential tremor (ET) may be due to oscillations within the olivocerebellar circuit. There is experimental evidence from animal models for such a mechanism, and clinical data indicate an abnormal function of the cerebellum in ET. Cerebellar tremor may be closely related to the tremor seen in advanced ET. The malfunction of the cerebellum causes a pathological feed-forward control. Additionally an oscillator within the cerebellum or its input/output pathways may cause cerebellar tremor. Almost nothing is known about the pathophysiology of dystonic tremor. Holmes tremor is based on a nigral and a cerebellar malfunction and presents clinically as the combination of tremor in Parkinson's disease and cerebellar tremor. Neuropathic tremor can be extremely disabling and is thought to be due to an abnormal interaction of the disturbances within the periphery and abnormal cerebellar feedback. Unlike the case of Parkinson's disease, functional neurosurgery of nonparkinsonian tremors is not yet based on a solid pathophysiological background.
Collapse
Affiliation(s)
- Günther Deuschl
- Department of Neurology, Christian-Albrechts-Universität, Kiel, Germany.
| | | |
Collapse
|
43
|
Abstract
Stimulation of the ventralis intermedius (Vim) is a treatment of severe tremor from various origins. The adjustment of electrical parameters is done when the lesion-like effects of the implant disappear. Each contact is assessed successively, by using a constant pulse width of 60 microsec and a frequency of 130 Hz or above and progressively increasing the voltage. At the same time, the tremor and possible side effects are monitored. The most frequent side effects are paresthesias, dysarthria, muscle contractions related to stimulation of the pyramidal tract, and cerebellar syndrome. Medications have to be adjusted slowly, and often, particularly in case of Parkinson's disease, it is difficult to decrease the dosage. It is important to teach the patient to switch the stimulator on or off and check that it is working. Patients need to be seen within the 3 months after implant, then occasionally according to the effect. In the long-term, some patients will develop some rebound of tremor when they switch off and/or some tolerance to the effect of the stimulator, which can be difficult to manage. In case of Parkinson's disease, motor fluctuations and dyskinesias, that does not respond to Vim stimulation, can occur.
Collapse
|
44
|
Young RF, Jacques S, Mark R, Kopyov O, Copcutt B, Posewitz A, Li F. Gamma knife thalamotomy for treatment of tremor: long-term results. J Neurosurg 2000. [DOI: 10.3171/jns.2000.93.supplement_3.0128] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Object. The purpose of this study was to investigate the long-term effects of gamma knife thalamotomy for treatment of disabling tremor.
Methods. One hundred fifty-eight patients underwent magnetic resonance imaging—guided radiosurgical nucleus ventralis intermedius (VIM) thalamotomy for the treatment of parkinsonian tremor (102 patients), essential tremor (52 patients), or tremor due to stroke, encephalitis, or cerebral trauma (four patients). Preoperative and postoperative blinded assessments were performed by a team of independent examiners skilled in the evolution of movement disorders. A single isocenter exposure with the 4-mm collimator helmet of the Leksell gamma knife unit was used to make the lesions.
In patients with Parkinson's disease 88.3% became fully or nearly tremor free, with a mean follow up of 52.5 months. Statistically significant improvements were seen in Unified Parkinson's Disease Rating Scale tremor scores and rigidity scores, and these improvements were maintained in 74 patients followed 4 years or longer.
In patients with essential tremor, 92.1% were fully or nearly tremor free postoperatively, but only 88.2% remained tremor free by 4 years or more post-GKS. Statistically significant improvements were seen in the Clinical Rating Scale for tremor in essential tremor patients and these improvements were well maintained in the 17 patients, followed 4 years or longer. Only 50% of patients with tremor of other origins improved significantly.
One patient sustained a transient complication and two patients sustained mild permanent side effects from the treatments.
Conclusions. Gamma knife VIM thalamotomy provides relief from tremor equivalent to that provided by radiofrequency thalamotomy or deep brain stimulation, but it is safer than either of these alternatives. Long-term follow up indicates that relief of tremor is well maintained. No long-term radiation-induced complications have been observed.
Collapse
|